← All trial listings Recruiting

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

ClinicalTrials.gov ID NCT07503444 · A Phase 3 Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study With Open-Label Extension to Evaluate the Efficacy And Safety of Fenfluramine Hydrochloride in Study Participants With Rett Syndrome

View the official record

At a glance

Status
Recruiting
Condition
Rett Syndrome
Phase
Phase 3
Ages
5 Years to 35 Years
Sex
All
Healthy volunteers
Not accepted
What is being studied
fenfluramine hydrochloride (drug); Placebo (other)
Sponsor
UCB BIOSCIENCES, Inc.
Target enrollment
200 participants
Study sites
46 open in Arkansas, Belgium, China, Florida, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Pennsylvania, Poland, Spain, Texas, United Kingdom, Washington
Start date
2026-07-14
Primary completion
2029-02-06

Common questions

Is NCT07503444 still recruiting?

ClinicalTrials.gov lists this trial as recruiting (checked 22 November 2026). It has 46 open or upcoming sites.

Who can take part in NCT07503444?

The record lists people aged 5 to 35 years with rett syndrome. The study team decides who is eligible, and the full criteria are on this page and in the official record.

Where is NCT07503444 running?

46 sites in Arkansas, Belgium, China, Florida, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Pennsylvania, Poland, Spain, Texas, United Kingdom, Washington, according to ClinicalTrials.gov.

What is being studied in NCT07503444?

It is a Phase 3 trial. The record lists these interventions: fenfluramine hydrochloride and Placebo. The sponsor is UCB BIOSCIENCES, Inc.

How many people will NCT07503444 enroll?

The record gives a target of 200 participants.

How do I sign up for NCT07503444?

Contact the study team listed in the official ClinicalTrials.gov record.

About this trial

From the ClinicalTrials.gov record.

The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).

Where it's running

SiteCityStateStatus
Ep0247 21010Little RockArkansasRecruiting
Ep0247 21009MiamiFloridaRecruiting
Ep0247 21011OrlandoFloridaRecruiting
Ep0247 21007AtlantaGeorgiaRecruiting
Ep0247 21003PhiladelphiaPennsylvaniaRecruiting
Ep0247 21005HoustonTexasRecruiting
Ep0247 21013IrvingTexasRecruiting
Ep0247 21004SeattleWashingtonRecruiting
Ep0247 11001BrusselsBelgiumRecruiting
Ep0247 11002EdegemBelgiumRecruiting
Ep0247 42001BeijingChinaRecruiting
Ep0247 42009ShanghaiChinaRecruiting
Ep0247 12005BrestFranceRecruiting
Ep0247 12003BronFranceRecruiting
Ep0247 12004MarseilleFranceRecruiting
Ep0247 12001ParisFranceRecruiting
Ep0247 12006ParisFranceRecruiting
Ep0247 13001TbilisiGeorgiaRecruiting
Ep0247 13002TbilisiGeorgiaRecruiting
Ep0247 14001VogtareuthGermanyRecruiting
Ep0247 15001BudapestHungaryRecruiting
Ep0247 15002DebrecenHungaryRecruiting
Ep0247 16001Ramat GanIsraelRecruiting
Ep0247 17007FlorenceItalyRecruiting
Ep0247 17003GenovaItalyRecruiting
Ep0247 17001MilanItalyRecruiting
Ep0247 17008NaplesItalyRecruiting
Ep0247 17002PisaItalyRecruiting
Ep0247 17009RomaItalyRecruiting
Ep0247 17006TroinaItalyRecruiting
Ep0247 43005Chiyoda-kuJapanRecruiting
Ep0247 43004KodairaJapanRecruiting
Ep0247 43001KurumeJapanRecruiting
Ep0247 43006Musashimurayama-shiJapanRecruiting
Ep0247 43002OsakaJapanRecruiting
Ep0247 43003Setagaya-kuJapanRecruiting
Ep0247 19003GdanskPolandRecruiting
Ep0247 19002KrakowPolandRecruiting
Ep0247 11106BarcelonaSpainRecruiting
Ep0247 11101MadridSpainRecruiting
Ep0247 11105MadridSpainRecruiting
Ep0247 11103MálagaSpainRecruiting
Ep0247 11102SevilleSpainRecruiting
Ep0247 11303ManchesterUnited KingdomRecruiting
Ep0247 11304NottinghamUnited KingdomRecruiting
Ep0247 11305Stoke-on-TrentUnited KingdomRecruiting
Full eligibility criteria (from the record)

Inclusion Criteria: * Participant has typical or classic Rett Syndrome (RTT) according to the RettSearch Consortium 2010 revised criteria * Participant has a documented disease-causing mutation or deletion in the methyl-CpG-binding protein 2 (MECP2) gene * Participant meets criteria for postregression for at least 6 months prior to Screening, defined as: * No loss or degradation of ambulation (including gait, coordination, or independence of walking/standing); * No loss or degradation of hand function; no loss or degradation of speech (including babbling, words, or previously developed communicative vocalizations); * No loss or degradation of nonverbal communicative or social skills (including eye gaze, using body to indicate communicative intent, or social attentiveness) * Participant has an Rett Syndrome Clinical Severity Scale (RTT-CSS) rating of 10 to 36 (inclusive) * Participant has a Clinical Global Impression-Severity (CGIS) score of ≥4 * Participant has a legal representative capable of providing signed informed consent on behalf of the participant as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. * Participant is aged 5 to 35 years of age (inclusive) at the time of first administration of investigational intervention. * Male or female. * Participant has a consistent caregiver who is ≥18 years of age at the Screening Visit. The caregiver needs to be able to complete the caregiver assessments defined for the entire study. Every attempt should be made to have the same evaluator complete the assessments for the duration of the study. Exclusion Criteria: * Participant has a history of lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. * Participant has clinically significant abnormality in vital signs according to the Investigator * Participant has an exclusionary cardiovascular or cardiopulmonary abnormality based on echocardiogram (ECHO), electrocardiogram (ECG), or physical examination, and is not approved for entry by the central cardiac reader. Exclusionary abnormalities include, but are not limited to: 1. Greater than trace aortic valve regurgitation. 2. Greater than mild mitral valve regurgitation. 3. Possible signs of pulmonary arterial hypertension (PAH) with abnormal pulmonary artery systolic pressure (PASP) or PASP ≥35 mmHg. 4. Evidence of left ventricular dysfunction (systolic or diastolic). 5. Clinically significant structural cardiac abnormality, including but not limited to mitral valve prolapse, atrial or ventricular septal defects, or patent ductus arteriosus with reversal of shunt (right to left shunt). Note: Patent foramen ovale without a reversal of shunt or a bicuspid aortic valve is not considered exclusionary * Participant has a clinically significant medical condition, including chronic obstructive pulmonary disease, interstitial lung disease, portal hypertension, or need for invasive mechanical ventilation (eg, via tracheostomy), or has had clinically relevant symptoms or a clinically significant illness currently or in the 4 weeks prior to the Screening Visit that would negatively impact study participation, collection of study data, or pose a risk to the participant * Participant is taking \>4 concomitant antiseizure medications (ASMs). Rescue medications are not included in the count

Other recruiting trials: Rett syndrome clinical trials

This listing shows only what the public ClinicalTrials.gov record NCT07503444 says, last updated there on 2026-11-17. It was checked against the registry on 22 November 2026. Taking part is voluntary, and the study team decides who is eligible. For the most current details, see the official record.